Predictive Oncology Faces Stiff Competition in Medical Supplies Industry

Analysts say rivals offer stronger growth potential than Predictive Oncology

Published on Feb. 14, 2026

Got story updates? Submit your updates here. ›

Predictive Oncology (NASDAQ:AGPU) is one of 28 publicly-traded companies in the 'Surgical, Medical, And Dental Instruments And Supplies' industry, but a new analysis shows it lags behind its competitors in several key areas. The report compares Predictive Oncology to related businesses based on factors like institutional ownership, risk, earnings, dividends, analyst recommendations, profitability and valuation.

Why it matters

As a smaller player in a crowded medical supplies market, Predictive Oncology faces challenges in standing out from more established rivals. The analysis suggests the company may need to focus on improving its financial performance and growth prospects to better compete.

The details

The analysis found that Predictive Oncology's rivals have higher revenue but lower earnings than the company. However, Predictive Oncology is trading at a lower price-to-earnings ratio, indicating it is currently more affordable than other companies in the industry. In terms of volatility, Predictive Oncology has a beta of 1.41, meaning its share price is 41% more volatile than the S&P 500, while its rivals have an average beta of 1.76. Analysts also gave Predictive Oncology's rivals stronger consensus ratings and higher potential upside compared to the company.

  • The analysis was published on February 14, 2026.

The players

Predictive Oncology

A knowledge-driven company that focuses on developing personalized cancer therapies using artificial intelligence, operating in four segments: Helomics, zPREDICTA, Soluble, and Skyline.

Predictive Oncology's rivals

A group of 28 publicly-traded companies in the 'Surgical, Medical, And Dental Instruments And Supplies' industry that compete with Predictive Oncology.

Got photos? Submit your photos here. ›

The takeaway

As a smaller player in the crowded medical supplies market, Predictive Oncology faces an uphill battle against more established and financially stronger rivals. To stay competitive, the company may need to focus on improving its financial performance, growth prospects, and differentiating its personalized cancer therapy offerings.